Literature DB >> 22830351

pKa, zinc- and serum albumin-binding of curcumin and two novel biologically-active chemically-modified curcumins.

Yu Zhang1, Lorne M Golub, Francis Johnson, Arnold Wishnia.   

Abstract

The pH equilibria and the zinc ion and bovine serum albumin (BSA) binding behavior of curcumin and two chemically modified curcumins (CMCs), namely 4-methoxycarbonylcurcumin (CMC 2.5) and 4-phenylaminocarbonyl bis-demethoxy curcumin (CMC 2.24), were studied, in order to understand the basis of their differential effects on the zinc-enzyme matrix metalloproteinases (MMPs) as well as the effect of charge state on their behavior in vivo. Moreover, all three compounds transform rapidly in the pH range 5-10, CMC 2.5 largely in one step, and CMC 2.24 and curcumin first in a rapid process to an intermediate form that still displays an enolic and two phenolic hydrogen-ion equilibria, and then more slowly to forms absorbing primarily in the lower UV and lacking the strong absorbance in the visible characteristic of the enol-centered chromophore. The binding of these compounds in one of the hydrophobic pockets of the major transport protein, serum albumin, was therefore studied. CMC 2.24 binds more strongly to BSA than curcumin, with a dissociation constant of 0.56±0.08 μM compared to 1.32±0.17 μM. Binding to BSA shifts the decomposition half-lives from tens of seconds to tens of hours. The zero-time acid dissociation constants (pK(a)) for species H(3)D, H(2)D(-), and HD(2-) are 8.41, 9.94 and 11.2; 6.98, 8.40 and 9.8; and 6.50 and 8.82 ; for curcumin, CMC 2.24, and CMC 2.5 respectively (there is no distinguishable pK(a3) for CMC 2.5). Zn(2+) binds most strongly to CMC 2.24 compared to CMC 2.5 and curcumin, with dissociation constants of 0.77±0.02, 1.88±0.07, and 1.39±0.09 mM. The increased acidity and Zn(2+) and BSA affinities of CMC 2.24 correlate with its greater biological activity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22830351     DOI: 10.2174/092986712802884240

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  15 in total

1.  A novel tricarbonylmethane agent (CMC2.24) reduces human pancreatic tumor growth in mice by targeting Ras.

Authors:  Naveen A Mallangada; Joselin M Vargas; Swaroopa Thomas; Matthew G DiGiovanni; Brandon M Vaeth; Matthew D Nemesure; Ruixue Wang; Joseph F LaComb; Jennie L Williams; Lorne M Golub; Francis Johnson; Gerardo G Mackenzie
Journal:  Mol Carcinog       Date:  2018-05-08       Impact factor: 4.784

2.  A Chemically Modified Curcumin (CMC 2.24) Inhibits Nuclear Factor κB Activation and Inflammatory Bone Loss in Murine Models of LPS-Induced Experimental Periodontitis and Diabetes-Associated Natural Periodontitis.

Authors:  Muna S Elburki; Carlos Rossa; Morgana R Guimarães-Stabili; Hsi-Ming Lee; Fabiana A Curylofo-Zotti; Francis Johnson; Lorne M Golub
Journal:  Inflammation       Date:  2017-08       Impact factor: 4.092

3.  Novel Chemically Modified Curcumin (CMC) Derivatives Inhibit Tyrosinase Activity and Melanin Synthesis in B16F10 Mouse Melanoma Cells.

Authors:  Shilpi Goenka; Francis Johnson; Sanford R Simon
Journal:  Biomolecules       Date:  2021-04-30

4.  Curcumin may impair iron status when fed to mice for six months.

Authors:  Dawn Chin; Patricia Huebbe; Jan Frank; Gerald Rimbach; Kathrin Pallauf
Journal:  Redox Biol       Date:  2014-02-28       Impact factor: 11.799

5.  4-methoxycarbonyl curcumin: a unique inhibitor of both inflammatory mediators and periodontal inflammation.

Authors:  Ying Gu; Hsi-Ming Lee; Nicole Napolitano; McKenzie Clemens; Yazhou Zhang; Timo Sorsa; Yu Zhang; Francis Johnson; Lorne M Golub
Journal:  Mediators Inflamm       Date:  2013-12-24       Impact factor: 4.711

Review 6.  Alternative pre-approved and novel therapies for the treatment of anthrax.

Authors:  Breanne M Head; Ethan Rubinstein; Adrienne F A Meyers
Journal:  BMC Infect Dis       Date:  2016-11-03       Impact factor: 3.090

7.  Local administration of curcumin-loaded nanoparticles effectively inhibits inflammation and bone resorption associated with experimental periodontal disease.

Authors:  Laura M G Zambrano; Dayane A Brandao; Fernanda R G Rocha; Raquel P Marsiglio; Ieda B Longo; Fernando L Primo; Antonio C Tedesco; Morgana R Guimaraes-Stabili; Carlos Rossa Junior
Journal:  Sci Rep       Date:  2018-04-27       Impact factor: 4.379

8.  A novel chemically modified curcumin reduces severity of experimental periodontal disease in rats: initial observations.

Authors:  Muna S Elburki; Carlos Rossa; Morgana R Guimaraes; Mark Goodenough; Hsi-Ming Lee; Fabiana A Curylofo; Yu Zhang; Francis Johnson; Lorne M Golub
Journal:  Mediators Inflamm       Date:  2014-06-29       Impact factor: 4.711

9.  Inhibition of anthrax lethal factor by curcumin and chemically modified curcumin derivatives.

Authors:  Anthony C Antonelli; Yu Zhang; Lorne M Golub; Francis Johnson; Sanford R Simon
Journal:  J Enzyme Inhib Med Chem       Date:  2013-10-09       Impact factor: 5.051

10.  A Novel Chemically Modified Curcumin "Normalizes" Wound-Healing in Rats with Experimentally Induced Type I Diabetes: Initial Studies.

Authors:  Yazhou Zhang; Steve A McClain; Hsi-Ming Lee; Muna S Elburki; Huiwen Yu; Ying Gu; Yu Zhang; Mark Wolff; Francis Johnson; Lorne M Golub
Journal:  J Diabetes Res       Date:  2016-04-13       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.